Addiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review

Destoop, Marianne; Morrens, Manuel; Coppens, Violette; Dom, Geert

doi:10.3389/fpsyt.2019.00311

Cited by 60 publications

(39 citation statements)

References 68 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several animal studies show that BDNF deficiency reduces sucrose preference, a loss of sensitivity to reward which has been suggested to model anhedonia (45)(46)(47)(48). Anhedonia is a core symptom of depression, and also plays an essential role in addictive disorders (49,50). In our sample, peripheral BDNF levels were indeed specifically related with self-reported anhedonia levels in the combined sample.…”

Section: Discussionsupporting

confidence: 59%

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

et al. 2020

View full text Add to dashboard Cite

Background: Alcohol Use Disorder (AUD) and depressive disorder often co-exist and have a shared heritability. This study aimed to investigate Brain-Derived Neurotrophic Factor (BDNF) and three Cell Adhesion Molecules (CAMs) as transdiagnostic biomarkers in AUD and depression co-morbidity. Methods: In a cross-sectional study, patients with AUD (n=22), AUD and depression (n=19), and healthy controls (n=20) were examined. Depression and anxiety severity were assessed using the Hamilton Depression Rating Scale and the Hamilton Anxiety Rating Scale. Anhedonia, alcohol use and dependence, craving, and social adaptation were assessed through self-report questionnaires. BDNF and CAM concentrations in peripheral serum were measured after overnight fasting using a Luminex assay. After controlling for age and gender, biomarker levels were compared across groups. The association between biomarker concentrations and symptom severity scales were explored using correlation and multiple regression analyses. Results: BDNF and Neuronal CAM were lower in patients with AUD with and without depression compared to healthy controls. No differences were observed for Vascular CAM-1 and Interstitial CAM-1. BDNF correlated negatively with anhedonia levels. BDNF, age and gender together explained 21% of variability in anhedonia levels. Conclusion: This pilot study suggests that peripheral levels of BDNF and NCAM might be reduced in AUD with and without comorbid mood disorder. Since low BDNF levels were

show abstract

Section: Discussionsupporting

confidence: 59%

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Animal and human studies were the focus in the paper of anhedonia as a transdiagnostic symptom. Anhedonia is a core symptom in depression and it is also involved in addictive disorders [ 74 ]. In this sense, dysregulation of the reward system and alterations in ventral extrapyramidal circuits were described in both disorders [ 75 , 76 ].…”

Section: Discussionmentioning

confidence: 99%

Alcohol Induced Depression: Clinical, Biological and Genetic Features

Farré

Tirado

Spataro

et al. 2020

JCM

View full text Add to dashboard Cite

Background: In clinical practice, there is the need to have clinical and biological markers to identify induced depression. The objective was to investigate clinical, biological and genetic differences between Primary Major Depression (Primary MD) and Alcohol Induced MD (AI-MD). Methods: Patients, of both genders, were recruited from psychiatric hospitalisation units. The PRISM instrument was used to establish the diagnoses. Data on socio-demographic/family history, clinical scales for depression, anxiety, personality and stressful life events were recorded. A blood test was performed analysing biochemical parameters and a Genome Wide Association Study (GWAS) to identify genetic markers associated with AI-MD. Results: A total of 80 patients were included (47 Primary MD and 33 AI-MD). The AI-MD group presented more medical comorbidities and less family history of depression. There were differences in traumatic life events, with higher scores in the AI-MD (14.21 ± 11.35 vs. 9.30 ± 7.38; p = 0.021). DSM-5 criteria were different between groups with higher prevalence of weight changes and less anhedonia, difficulties in concentration and suicidal thoughts in the AI-MD. None of the genetic variants reached significance beyond multiple testing thresholds; however, some suggestive variants were observed. Conclusions: This study has found clinical and biological features that may help physicians to identify AI-MD and improve its therapeutic approach.

show abstract

“…Anhedonia, i.e. a markedly diminished interest or pleasure in activities, is associated with both mood and substance abuse disorders [see criterion v(c) in Box 3] (Destoop et al , 2019). It is common for individuals with problematic gambling [see criterion v(a) in Box 3] to have comorbid psychiatric disorders, such as current mood disorders, alcohol use disorders, and anxiety disorders (DowLing et al , 2015; Sundqvist and Rosendahl, 2019).…”

Section: Directions For Future Researchmentioning

confidence: 99%